全球心臟生物標記診斷產業（2024-2029）

Global Cardiac Biomarkers Diagnostics Industry, 2024-2029

出版日期: 2025年01月20日 | 出版商:

Frost & Sullivan | 英文 70 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

心血管疾病盛行率上升和高靈敏度 POCT 推動心臟生物標記診斷的變革性成長

由於心血管疾病 (CVD) 盛行率不斷上升、多重生物標記和診斷檢測技術的進步、 POCT 的採用率不斷提高以及對預防性醫療保健的重視，全球心臟生物標記診斷市場預計將實現強勁成長。心血管疾病是全球主要死亡原因之一，凸顯了早期發現和早期療育的重要性。世界衛生組織（WHO）估計，2030年將有2,330萬人死於心血管疾病。其中，急性心肌梗塞（AMI）、急性冠狀動脈症候群、心臟衰竭最受研究人員和醫學專業人士的關注。急性心肌梗塞是一種常見疾病，佔全球死亡人數的三分之一，因此 AMI 成為世衛組織的重點。

羅氏公司的 Elecsys® Troponin T hs 等針對 AMI 的高靈敏度心肌肌鈣蛋白檢測方法的進展已成為歐洲和亞洲各地急診室必不可少的工具，有助於加快診斷速度並改善患者預後。亞太地區是一個快速成長的地區，擁有巨大的未開發成長潛力。

實驗室測試和 POCT 在心臟生物標記診斷市場中各自發揮不同的重要作用。實驗室測試具有很高的靈敏度和準確性，對於詳細的風險評估和持續監測至關重要。相較之下，POCT 可在患者附近快速提供結果，有助於在緊急情況下和偏遠地區快速做出決策。速度和準確性的平衡確保了兩種測試的持續需求。

由於生物標記檢測和技術的進步，以及對更高檢測準確性和靈敏度的持續追求，市場競爭處於中等水平。六家公司主導市場：羅氏診斷、雅培快速診斷（原為 Alere）、Quidel Corporation、bioMerieux、西門子醫療和丹納赫公司。實驗室分析設備是一個合併的細分市場，因為公司數量有限，而分析儀器則更加分散，因為公司數量眾多。該實驗室對於檢查和複雜分析至關重要，管理多個標記組（例如 BNP、CK-MB、肌紅蛋白、肌鈣蛋白）以提供心臟健康的全面視圖。

這項研究服務概述了全球心臟生物標記診斷產業以及 2024 年至 2029 年全球市場收益的六年預測。報告涵蓋四個地區：北美、歐洲、亞太、中東、北非和南亞（MENASA）以及拉丁美洲。心臟生物標記診斷市場的詳細研究包括：

經監管機構核准並在中心實驗室中廣泛使用的實驗室標準化測試：該實驗室心臟生物標記領域涵蓋的生物標記包括肌鈣蛋白、高敏肌鈣蛋白、BNP/NT-proBNP、hs-CRP、CK-MB 生物標記以及其他生物標記，如神經調節蛋白-1BETA、ST2、半乳霜凝集素、血脂譜、乳醣素、血脂譜、乳醣類等。
POCT 涵蓋全球市場的肌鈣蛋白、BNP、CK-MB、D-二聚體、肌紅蛋白生物標記。本研究排除了未經上市前核准而內部設計用於特殊用途的實驗室開發的測試。

心臟生物標記是響應心臟損傷或壓力而釋放到血液中的物質。它們用於心臟衰竭、心肌梗塞和急性冠狀動脈症候群等疾病的診斷、風險評估和管理。檢測地點可能包括獨立實驗室、醫生辦公室、緊急護理機構、療養院、醫院和急診/室。心臟生物標記診斷範圍包括供應商分析，包括儀器、消耗品、試劑、試劑套件和檢測試劑。

成長指標
成長動力
成長抑制因素
檢測心血管疾病的新生物標記
心臟生物標記診斷的趨勢
數位健康和診斷整合模型：心臟診斷
預測考慮因素
收益預測
收益預測分析
按測試類型預測收益
收益預測分析
各地區收益預測
區域收益預測分析：北美
各地區收益分析：歐洲
各地區收益分析：亞太地區
按地區分類的收益分析：中東、北非、南亞和拉丁美洲
價格趨勢及預測分析
收益佔有率
收益佔有率分析
競賽矩陣
全球心臟生物標記診斷產業：值得關注的活動

成長機會分析：實驗室測試的成長要素

成長指標：基於實驗室的心臟生物標記診斷
基於實驗室的心臟生物標記診斷收益預測
基於實驗室的心臟生物標記診斷收益預測分析

成長機會分析：POCT 的成長要素

成長指標：POCT 心臟生物標記診斷
POCT 心臟生物標記診斷的收益預測
POCT心臟生物標記診斷收益預測分析

全球心臟生物標記診斷產業的成長機會領域

成長機會1：高靈敏度檢測 (HSA)
成長機會2：用於全面診斷的多標記心臟檢測組
成長機會3：面向區域和新興市場的 POCT 設備
成長機會#4：與穿戴式裝置和應用程式整合，實現早期檢測和即時監控

附錄與後續步驟

成長機會的好處和影響
後續步驟Next steps
附件列表
免責聲明

簡介目錄

Product Code: PFRK-55

Rising Prevalence of CVD and High Sensitivity POCT Driving Transformational Growth in Cardiac Biomarkers Diagnostics

The global cardiac biomarkers diagnostics market is forecast to record robust growth with the increased prevalence of cardiovascular disease (CVD), multiplex biomarkers, advancements in diagnostic testing technology, higher POCT adoption rates, and an intensive focus on preventive healthcare. CVDs are a leading cause of mortality globally, highlighting the importance of early detection and intervention. The World Health Organization (WHO) estimates that in 2030, 23.3 million individuals will die from CVDs. Among these, acute myocardial infarction (AMI), acute coronary syndrome, and heart failure capture the greatest interest of researchers and healthcare professionals. Due to the high frequency-one-third of deaths-of this pathology globally, AMI is a key focus for WHO.

Advancements in high-sensitivity cardiac troponin assays for AMI, such as Roche's Elecsys(R) Troponin T hs make them vital in emergency departments throughout Europe and Asia, speeding up diagnosis and enhancing patient outcomes. Asia-Pacific is the fastest-growing region with high, untapped growth potential.

Lab-based and POCT segments serve critical, distinct roles in the cardiac biomarkers diagnostics market. Lab tests provide high sensitivity and precision, which is essential for detailed risk assessment and ongoing observation. In contrast, POCT delivers rapid results at the patient's side, facilitating prompt decision-making in emergencies and remote locations. This balance of speed and accuracy ensures continued demand for both testing methods.

The market is moderately competitive driven by advances in biomarkers assays and technology alongside a continuous push for enhanced accuracy and high sensitivity of assays. Six players dominate the market: Roche Diagnostics, Abbott Rapid Diagnostics (formally Alere), Quidel Corporation, bioMerieux, Siemens Healthineers, and Danaher Corporation. There are limited players in lab analyzers, making this segment consolidated, while the assays space is more fragmented owing to the presence of numerous players. Labs are essential for precise testing and complex analysis, managing multi-marker panels (e.g., BNP, CK-MB, myoglobin, and troponin) to provide a comprehensive view of cardiac health.

This research service provides an overview of the global cardiac biomarkers diagnostics industry and a 6-year global market revenue forecast from 2024 to 2029. The geographical scope covers four regions: North America, Europe, Asia-Pacific, and the Middle East, North Africa, and South Asia (MENASA) and Latin America. The detailed examination of the cardiac biomarkers diagnostics market includes:

Lab-based standardized tests that are approved by regulators and widely used by centralized labs. The biomarkers covered in this lab-based cardiac biomarkers segment include troponins, high-sensitivity troponins, BNP/NT-proBNP, hs-CRP, CK-MB biomarkers, and other biomarkers such as Neuregulin-1beta, ST2, Galectin, lipid profiles, and Copeptin.
POCT covers troponins, BNP, CK-MB, D-dimer, and myoglobin biomarkers for the global market. The study excludes laboratory-developed tests that are internally designed for specialized use without pre-market approvals.

Cardiac biomarkers are substances released into the bloodstream in response to heart damage or stress. They diagnose, assess risk, and manage conditions such as heart failure, myocardial infarction, and acute coronary syndrome. Testing locations discussed in the study include independent laboratories, physicians' offices, urgent care facilities, nursing facilities, hospitals, and emergency departments/rooms. The cardiac biomarkers diagnostics coverage includes vendor analysis encompassing instruments, consumables, reagents, kits, and assays.

Research Scope

Scope of Analysis
Segmentation
History of Cardiac Biomarkers
Cardiac Biomarkers
Mechanism of Cardiac Biomarkers in Heart Failure

Growth Environment: Transformation in the Cardiac Biomarkers Diagnostics Industry

Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Cardiac Biomarkers Diagnostics Industry

Ecosystem in the Global Cardiac Biomarkers Diagnostics Industry

Competitive Environment
Key Competitors by Region

Growth Generator in the Cardiac Biomarkers Diagnostics Industry

Growth Metrics
Growth Drivers
Growth Restraints
Emerging Biomarkers for the Detection of Cardiovascular Diseases
Cardiac Biomarkers Diagnostics Trends
Digital Health and Diagnostics Inter Convergence Model: Cardiac Diagnostics
Forecast Considerations
Revenue Forecast
Revenue Forecast Analysis
Revenue Forecast by Test Type
Revenue Forecast Analysis
Revenue Forecast by Region
Revenue Forecast Analysis by Region: NA
Revenue Forecast Analysis by Region: Europe
Revenue Forecast Analysis by Region: APAC
Revenue Forecast Analysis by Region: MENASA and Latin America
Pricing Trends and Forecast Analysis
Revenue Share
Revenue Share Analysis
Competitor Matrix
Global Cardiac Biomarkers Diagnostics Industry: Notable Activities

Growth Opportunity Analysis: Growth Generator in Lab-based Tests

Growth Metrics: Lab-based Cardiac Biomarkers Diagnostics
Lab-based Cardiac Biomarkers Diagnostics Revenue Forecast
Lab-based Cardiac Biomarkers Diagnostics Revenue Forecast Analysis

Growth Opportunity Analysis: Growth Generator in POCT

Growth Metrics: POCT Cardiac Biomarkers Diagnostics
POCT Cardiac Biomarkers Diagnostics Revenue Forecast
POCT Cardiac Biomarkers Diagnostics Revenue Forecast Analysis

Growth Opportunity Universe in the Global Cardiac Biomarkers Diagnostics Industry

Growth Opportunity 1: High Sensitivity Assays (HSAs)
Growth Opportunity 2: Multi-marker Cardiac Panels for Comprehensive Diagnostics
Growth Opportunity 3: POCT Devices for Rural and Emerging Markets
Growth Opportunity 4: Convergence with Wearables and Apps for Early Detection and Real-time Monitoring